JP5513126B2 - 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 - Google Patents

肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 Download PDF

Info

Publication number
JP5513126B2
JP5513126B2 JP2009541912A JP2009541912A JP5513126B2 JP 5513126 B2 JP5513126 B2 JP 5513126B2 JP 2009541912 A JP2009541912 A JP 2009541912A JP 2009541912 A JP2009541912 A JP 2009541912A JP 5513126 B2 JP5513126 B2 JP 5513126B2
Authority
JP
Japan
Prior art keywords
xanthohumol
isoxanthohumol
active substance
liver
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513360A5 (enExample
JP2010513360A (ja
Inventor
ヘレルブランド、クラウス
Original Assignee
フラキサン ゲーエムベーハー ウント コー． カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラキサン ゲーエムベーハー ウント コー． カーゲー filed Critical フラキサン ゲーエムベーハー ウント コー． カーゲー
Publication of JP2010513360A publication Critical patent/JP2010513360A/ja
Publication of JP2010513360A5 publication Critical patent/JP2010513360A5/ja
Application granted granted Critical
Publication of JP5513126B2 publication Critical patent/JP5513126B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2009541912A 2006-12-22 2007-12-21 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 Expired - Fee Related JP5513126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
DE102006062264.2 2006-12-22
PCT/EP2007/011358 WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen

Publications (3)

Publication Number Publication Date
JP2010513360A JP2010513360A (ja) 2010-04-30
JP2010513360A5 JP2010513360A5 (enExample) 2011-01-13
JP5513126B2 true JP5513126B2 (ja) 2014-06-04

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541912A Expired - Fee Related JP5513126B2 (ja) 2006-12-22 2007-12-21 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用

Country Status (7)

Country Link
US (1) US20100029757A1 (enExample)
EP (1) EP2120906B1 (enExample)
JP (1) JP5513126B2 (enExample)
CA (1) CA2672155C (enExample)
DE (1) DE102006062264A1 (enExample)
RU (1) RU2454996C2 (enExample)
WO (1) WO2008077618A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2441665T3 (es) * 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
EP2861202B1 (en) 2012-06-18 2018-07-18 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
HUE052388T2 (hu) 2012-07-26 2021-04-28 Arcaini Antonio Pörkölt kivonatot és xantohumolt tartalmazó kompozíciók alkalmazásai
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
WO2014099490A2 (en) 2012-12-17 2014-06-26 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
WO2017001020A1 (de) 2015-07-02 2017-01-05 Flaxan Gmbh & Co. Kg Substanz auf hopfenbasis sowie verwendung der substanz
AU2017384173A1 (en) * 2016-12-20 2019-06-27 Suntory Holdings Limited Lipid metabolism-promoting composition including isoxanthohumol
CA3148455A1 (en) 2017-07-11 2019-01-17 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US11786484B2 (en) 2018-07-11 2023-10-17 Aquanova Ag Xanthohumol solubilizate
EP3820527B1 (de) * 2018-07-11 2023-08-23 Aquanova AG Xanthohumol-solubilisat
US20210186924A1 (en) * 2018-08-10 2021-06-24 Suntory Holdings Limited Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level
JPWO2020031953A1 (ja) * 2018-08-10 2021-08-10 サントリーホールディングス株式会社 微生物増殖抑制剤、微生物汚染防止方法、及び、飲料
CN112566515A (zh) * 2018-08-10 2021-03-26 三得利控股株式会社 肠内环境改善用组合物及肠内菌丛的改善方法
US20210161857A1 (en) * 2018-08-10 2021-06-03 Suntory Holdings Limited Composition and method for suppressing increase in blood glucose level
EP4291307A4 (en) * 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
AU2022308043A1 (en) * 2021-07-09 2024-01-25 INNOX Corp. Prenylated chalcone and flavonoid compositions for use in treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
KR100594400B1 (ko) * 1996-08-30 2006-07-03 엔피에스 파마슈티칼즈, 인코포레이티드 이소발레린산 유도체 ｃｎｓ 억제제를 이용한 경련, 경직의 치료
JP2003504327A (ja) 1999-07-08 2003-02-04 プレンダーガスト、パトリック、ティ． 感染症の治療を目的としたフラボン類、クマリン類および関連化合物の使用
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
US20040002423A1 (en) * 2000-04-10 2004-01-01 Hiromu Ohnogi Remedies
BR0208418A (pt) * 2001-04-05 2004-03-30 Unilever Nv Uso de isoxantohumol e/ou xantohumol, método para administrar isoxantohumol e/ou xantohumol a seres humanos em necessidade de receber um componente ani-inflamatório ou anti-envelhecimento, e, produto alimentìcio
JPWO2003006037A1 (ja) * 2001-07-13 2004-10-28 タカラバイオ株式会社 治療剤
DE10308864B4 (de) 2003-02-28 2007-03-01 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
WO2006099015A2 (en) 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
CA2618613A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Also Published As

Publication number Publication date
RU2454996C2 (ru) 2012-07-10
CA2672155A1 (en) 2008-07-03
JP2010513360A (ja) 2010-04-30
EP2120906B1 (de) 2015-04-22
WO2008077618A1 (de) 2008-07-03
DE102006062264A1 (de) 2008-06-26
RU2009128213A (ru) 2011-01-27
CA2672155C (en) 2013-10-01
US20100029757A1 (en) 2010-02-04
EP2120906A1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
JP5513126B2 (ja) 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
AU780161B2 (en) Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
EP3391893A1 (en) Medicine composition for treating leukemia and preparation method therefor
JP2015528474A (ja) 脳梗塞の予防及び治療のための薬の調製上の３−ｎ−ブチルイソインドリノンの応用
JP2004091473A (ja) 色素沈着改善治療薬
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
KR20220161413A (ko) 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물
CN105078944A (zh) Isopaucifloral F在制备抗骨质疏松药物中的用途
CN104758304A (zh) 三七皂苷r1的医药用途
EP1263435B1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
US20140066519A1 (en) Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
JP2018519342A (ja) ホップに基づく物質およびその物質の使用
CN102076346B (zh) 一种人用药物组合物及铋或锌剂的制备
JP6184960B2 (ja) メラトニンの新規用途
CN104758305A (zh) 三七皂苷Ft1的医药用途
CN106822152B (zh) 一种药物组合物及其应用
KR102838311B1 (ko) Rls 치료를 위한 님
CN101579389A (zh) 一种治疗骨质疏松症的药物组合物
CN107648249A (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
JP2004115420A (ja) 気管支及び肺疾患の治療剤及びそれを含有する飲食品
CN120549927A (zh) 异喹啉生物碱ys-49在制备治疗流行性乙型脑炎病毒感染药物中的应用
CN105833051A (zh) 一种护心通络的药物组合物及含其制剂与应用
CN115040545A (zh) 鸡胆粉在制备解酒护肝药物中的用途
JP2005035918A (ja) いびき防止剤
SK500572021A3 (sk) Spôsob výroby výživových doplnkov vo forme perorálnych produktov vykazujúcich biocídne vlastnosti vo vzťahu k vírusom a/alebo baktériám a výživový doplnok získaný týmto spôsobom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140327

R150 Certificate of patent or registration of utility model

Ref document number: 5513126

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees